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Abstract
BACKGROUND: Cancer anemia causes fatigue and
correlates with poor treatment outcome. Erythropoie-
tin has been introduced in an attempt to correct these
defects. However, five recent clinical trials reported a
negative impact of erythropoietin on survival and/or
tumor control, indicating that experimental evaluation of
a possible direct effect of erythropoietin on cancer cells
is required. Cancer recurrence is thought to rely on the
proliferation of cancer initiating cells (CICs). In breast
cancer, CICs can be identified by phenotypic markers
and their fate is controlled by the Notch pathway.
METHODS: In this study, we investigated the effect of
erythropoietin on CICs in breast cancer cell lines. Levels
of erythropoietin receptor (EpoR), CD24, CD44, Jagged-1
expression, and activation of Notch-1 were assessed by
flow cytometry. Self-renewing capacity of CICs was in-
vestigated in sphere formation assays. RESULTS: EpoR
expression was found on the surface of CICs. Recombi-
nant human Epo (rhEpo) increased the numbers of CICs
and self-renewing capacity in a Notch-dependent fash-
ion by induction of Jagged-1. Inhibitors of the Notch
pathway and PI3-kinase blocked both effects. CONCLU-
SIONS: Erythropoietin functionally affects CICs directly.
Our observation may explain the negative impact of
recombinant Epo on local control and survival of cancer
patients with EpoR-positive tumors.
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Introduction
Cancer-related and chemotherapy-induced anemia nega-
tively impacts the quality of life of many cancer patients and
is accompanied by a poor prognosis [1–5]. Therefore, ane-
mia is frequently corrected by blood transfusions or appli-
cation of erythropoiesis-stimulating agents (ESAs) [7].
However, three randomized clinical studies reported a neg-
ative impact of ESAs on overall survival and local tumor
control in breast [8], head and neck [9], and non–small cell
lung cancer patients [10]. More recently, two large clinical
trials (DAHANCA 10 and Anemia of Cancer, study by
Amgen) were stopped after interim analyses showed in-
creased death rates in patients treated with ESAs. Whereas
some of the patients treated with ESAs experienced thrombo-
embolic events that could be easily related to changes in blood
rheology, a negative impact of ESAs on local tumor control
most likely resulted from more complex interactions.
We have recently demonstrated that overexpression of the
erythropoietin receptor (EpoR) increased the clonogenicity of
cancer cells [11] and that local control and overall survival in
patients receiving recombinant human erythropoietin (rhEpo)
were only negatively affected if the cancers stained positive
using an anti–EpoR antibody [12]. A better understanding of
the mechanisms underlying these rhEpo-related effects may
allow rational selection of patients for treatment and uncover
novel targets to improve cancer treatment outcome.
One view of cancer is that it arises from and is maintained by
a small number of cancer stem cells (CSCs), which have the
ability to self-renew whereas their progenies do not [13]. CSCs
can now be identified prospectively in brain tumors [14], breast
cancer [15], prostate cancer [16], cancer of the head and neck
[6], pancreatic cancer [17], and melanoma [18]. The hypothesis
is that CSCs are responsible for the regrowth and metastatic
spread of a tumor and the efficacy of any given treatment
depends on the killing of this population of cells [13]. In breast
cancer, a CD44+/CD24/low cell population can be isolated from
patient tumor samples or established cell lines that are highly
enriched for the putative breast cancer stem cell population
exhibiting a 3-log increased tumorigenicity [15].
Furthermore, Dontu et al. [19] demonstrated that mammary
development relies on the developmental Notch signaling
pathway that regulates the fate of mammary stem cells. On
binding of Notch ligands, the Notch receptors undergo intra-
membranous cleavage by the g-secretase protease complex.
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This releases the intracellular domain of the receptor
(Notch–ICD) for translocation into the nucleus, where it
switches the function of CBF-1 from a transcriptional repres-
sor into an activator. Function of g-secretase can be blocked
by specific inhibitors, which are already in clinical trials for
patients suffering from Alzheimer’s disease [20].
The stem cell in breast cancer that is capable of repop-
ulating a tumor from a single cell has not yet been firmly
characterized. Therefore, we will join others in calling the
population of CD44+/CD24/low putative stem cells, breast
cancer– initiating cells (BCICs). Adopting a technique for the
propagation of normal mammary stem cells [21], Ponti et al.
[22] recently demonstrated that BCICs can be propagated as
mammospheres in vitro. BCICs derived from MCF-7 breast
cancer cells mimicked the phenotype and tumorigenicity of
BCICs derived from primary estrogen receptor–positive
breast cancers. This offers an invaluable tool to study the
treatment responses of BCICs directly and to compare them
to vast literature gained using breast cancer cell lines in the
past. Using the same techniques as Ponti et al., we were able
to enrich mammospheres to contain up to 40% of CD44+/
CD24/low cells and demonstrate that BCICs are a radio-
resistant subpopulation of cancer cells. Remarkably, the
number of BCICs increased after sublethal fractionated ir-
radiation in vitro. Radiation activated the developmental
Notch signaling pathway and inhibition of this pathway pre-
vented the radiation-induced increase in the number of
BCICs [23]. The relevance of this cell population was under-
lined by two other studies demonstrating that BCICs have
enhanced invasive properties [24] and that the most early
disseminated cells in the bone marrow of breast cancer
patients exhibit the CD44+/CD24/low phenotype [25]. Such
cells are also resistant to conventional cancer treatment
[23,26,27].
We hypothesized that rhEpo might act on BCICs to
increase the size of the BCICs’ population and compromise
tumor control in breast cancer patients receiving rhEpo
treatment. We addressed our hypothesis using our estab-
lished in vitro BCIC system with MCF-7, T47D, and MDA-
MB-231 breast cancer cell lines, which account for two thirds
of all experimental literature on breast cancer [28].
We found that pharmacological concentrations of rhEpo
increased the number of putative BCICs in established
breast cancer cell lines. The increase was mediated by the
activation of the Notch signaling pathway, could be blocked
by inhibiting this pathway, and mimicked by overexpression
of a constitutively active Notch-1 receptor. Notch activation
occurred through the induction of the Notch receptor ligand
Jagged-1 in a phosphoinositide-3 kinase (PI3K)-dependent
fashion and could be blocked by a PI3K inhibitor.
Methods
Cell Culture
MCF-7, T47D, and MDA-MB-231 breast cancer cells
were purchased from the American Type Culture Corpora-
tion (Manassas, VA) and cultured in log-growth phase in min-
imum essential medium (MCF-7 and T47D) (Cellgro, Kansas
City, MO) (supplemented with 0.1 mM nonessential amino
acids and 1 mM sodium pyruvate) and Dulbecco’s modified
Eagle’s medium (DMEM) (MDA-MB-231) (Cellgro), respec-
tively, after supplementing with 10% heat-inactivated fetal
calf serum and 0.01 mg/ml bovine insulin (Sigma, St. Louis,
MO) at 37jC in a humidified atmosphere (5%CO2). Mammo-
sphere cultures were established as described by Ponti
et al. [22] under serum-free conditions in phenol red–free
DMEM/F12, supplemented with 0.4% bovine serum albumin,
20 ng/ml basic fibroblast growth factor (Sigma), and 10 ng/ml
epidermal growth factor (Sigma). Cultures were fed with
fresh growth factors every 3 days.
Transfection
All plasmid DNA were prepared using a commercial
DNA extraction and isolation kit (Midiprep; Quiagen, Valencia
CA). The Notch–ICD plasmid [29] was a gift from Dr. L. Miele
(Loyola University Medical Center). The pNICD plasmid was
constructed by cloning the intracellular domain of Notch-1
(5309–7655 bp) into the expression vector pcDNA3 (Invitro-
gen, Carlsbad, CA). The empty pcDNA3 vector was used as a
control. MCF-7 cells were transfected with the pNICD plasmid
or the pcDNA3 control vector using Lipofectamine2000 (In-
vitrogen) and OptiMEM (Invitrogen). After 24 hours, the cells
were replated and maintained under 1 mg/ml neomycin
(Sigma) selection. Individual clones were selected, grown in
the presence of 1 mg/ml neomycin, and tested for the expres-
sion of intracellular Notch-1 (Notch-1–ICD). Clones overex-
pressing intracellular Notch-1 were expanded under neomycin
selection to generate stable expression of MCF-7–pNICD
and MCF-7–pcDNA3 cell lines.
Drug Treatment
RhEpo (1 IU/ml) treatment of monolayer cultures of MCF-
7 cells was performed from day 2 to 4 after plating. Cells were
harvested on day 5 when flow cytometry was performed to
assess the cells’ phenotypes. The g-secretase inhibitor (GSI),
GSI XVII (InSolution; Calbiochem, San Diego, CA), was
Figure 1. MCF-7, T47D, and MDA-MB-231 monolayer cells were serum-
starved for 5 hours, trypsinized, and analyzed for EpoR-expression on the cell
surface by flow cytometry. EpoR was expressed on CD44+/CD24/low cells,
the putative stem cell population (gray) as well as on unselected cells (black).
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added at a final concentration of 5 mM (0.1% final concentra-
tion of DMSO). LY294002 (Calbiochem) was dissolved in
DMSO and added at a final concentration of 10 mM. Control
cells received 0.1% DMSO only. Cells were serum-starved
for 5 hours before the start of the experiment to prevent
EpoR internalization through binding of fetal calf serum–
derived erythropoietin (Epo). Serum starvation in long-term
experiments in which cells were treated with rhEpo for 3
consecutive days was not tolerated by the cells and was
therefore omitted.
Flow Cytometry
For analysis of CD24 and CD44 expression, cells were
labeled using a mouse anti–human CD24–fluorescein iso-
thiocyanate (BD Pharmingen, San Jose, CA) and a mouse
anti–human CD44–phycoerythrin (PE) (BD Pharmingen). In
Figure 2. (A) FACS analysis detecting the size of the CD44+/CD24/low cell population in monolayers and supernatant of MCF-7 cells. Treatment with rhEpo (3 
1 IU/ml) increased the size of this population 4.8-fold from 2 ± 0.08% to 9.5 ± 1.8% (P < .01, Student’s t test). Data from four independent experiments are shown.
(B) Representative FACS analysis of MCF-7 monolayer cultures treated with rhEpo (3  1 IU/ml) for 3 consecutive days. About 0.9% of the cell in the adherent cell
population was CD44+/CD24/low ( left panel). Treatment with rhEpo increased the frequency of CD44+/CD24/low cells in the supernatant from 2% (middle panel)
to 14.9% (right panel). (C and D) Primary sphere formation assay of MCF-7 (C) or MDA-MB-231 (D) cells treated with rhEpo (3  1 IU/ml) for 3 consecutive days.
RhEpo increased the rate of primary spheres formation (MCF-7: 1 ± 0.4% for untreated cells, 2.9 ± 0.6% for Epo-treated cells; MDA-MB-231: 1.2 ± 0.6 for
untreated cells, 4.5 ± 1.1% for Epo-treated cells, P < .01, two-sided Student’s t test; means ± SEM). Preincubation (30 minutes) with GSI (5 M) treatment
prevented the rhEpo-induced increase in primary sphere formation (MCF-7: GSI-treated cells, 1 ± 0.4%; Epo + GSI– treated cells, 1.5 ± 0.4%; MDA-MB-231: GSI-
treated cells, 1.5 ± 0.7%; Epo + GSI– treated cells, 1.1 ± 0.8%).
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experiments investigating EpoR expression, cells were serum-
starved for 5 hours. For detecting EpoR expression, cells
were labeled with a monoclonal fluorescein isothiocyanate–
conjugated mouse anti–human EpoR antibody (FAB307F;
R&D Systems, Minneapolis, MN), a PE/Cy5–conjugated
mouse anti–human CD44 antibody (BioLegend, San Diego,
CA), and a PE-conjugated mouse anti–CD24 antibody (Beck-
man Coulter, Fullerton, CA) using standard protocols. For
analysis of Jagged-1 expression and Notch activation, cells
were harvested, fixed in 4% paraformaldehyde for 10 minutes
at room temperature, permeabilized with 0.5% saponin, and
incubated with a rabbit anti–human Jagged-1 (Santa Cruz
Biotechnology, Santa Cruz, CA) or a rabbit anti–human
cleaved Notch-1 antibody (Cell Signaling Inc., Danvers, MA)
and fluorochrome-conjugated secondary antibodies using
standard protocols. Flow cytometry was performed on a
FACScalibur flow cytometer using the CellQuest software
package (BD Biosciences, San Jose, CA).
Primary Sphere Formation Assay
The frequency of cells in the nonadherent population of
monolayer cultures that were capable of initiating sphere
formation was assessed by harvesting, washing, and resus-
pending cells in phenol red–free DMEM/F12 medium (sup-
plemented with 0.4% bovine serum albumin, 20 ng/ml basic
fibroblast growth factor, and 10 ng/ml epidermal growth fac-
tor), and passing them through a 40-mm sieve. Cells were
then counted, diluted, and plated at clonal density into 96-
well plates. Mammospheres were counted on day 5.
Results
rhEpo Increases the Size of the Putative BCIC Population
The expression of EpoR on breast cancer cells has been
described by others [30], but not its expression on CD44+/
CD24/low cells. MCF-7, T47D, and MDA-MB-231 CD44+/
CD24/low cells were found to express levels of EpoR com-
parable to levels of EpoR on unselected cells (Figure 1).
To test if rhEpomodulates the size of the CD44+/CD24/low
population,MCF-7monolayer cultureswere treatedwith 1 IU/ml
rhEpo for 3 consecutive days (days 2–4 of culture). About
24 hours later, monolayer cells and cells floating in the
supernatant were analyzed for CD24 and CD44 expression.
Cells were stained with antibodies against CD24 and CD44
and the size of the CD44+/CD24/low population of cells was
analyzed by flow cytometry. Treatment with rhEpo did not
change the number of CD44+/CD24/low in the adherent cell
population but increased the number of CD44+/CD24/low
cells in the supernatant almost 5-fold from 2% (± 0.3%) to
9.5% (± 1.8%) (means ± SEM; P < .01, Student’s t test)
(Figure 2, A and B).
The effect of rhEpo was also demonstrated by its ability to
increase in primary sphere formation by cells taken from the
supernatant of MCF-7 or MDA-MB-231 monolayer cultures
and plated at clonal densities into 96-well plates. Cells de-
rived from cultures treated with 1 IU/ml rhEpo on 3 con-
secutive days (days 2–4 of culture) showed a significant
increase in primary sphere formation (MCF-7: 1 ± 0.4% for
untreated cells, 2.9 ± 0.6% for Epo-treated cells; MDA-MB-
231: 1.2 ± 0.6 for untreated cells, 4.5 ± 1.1% for Epo-treated
cells, P < .01, two-sided Student’s t test; means ± SEM)
(Figure 2, C and D).
rhEpo Increases the Number of BCICs in a
Notch-Dependent Fashion
We have previously shown that activation of the Notch
signaling pathway increases the number of BCICs [23]. To
investigate if blocking activation of the Notch-1 pathway would
prevent Epo-induced increases in the number of BCICs,
monolayer cultures were pretreated with GSI, 30 minutes
before each daily treatment with rhEpo. GSI treatment pre-
vented the rhEpo-induced increase in primary sphere forma-
tion (MCF-7: GSI-treated cells, 1 ± 0.4%; Epo + GSI–treated
Figure 2. (continued)
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Figure 3. (A) Treatment of MCF-7 monolayer culture with 1 IU/ml rhEpo for 2 hours caused a 1.4 ± 0.16– fold (mean ± SEM, P = .041, n = 3, two-sided paired
Student’s t test) induction of Jagged-1 expression. (B) Treatment of MCF-7 monolayer culture with 1 IU/ml rhEpo for 2 hours caused a 1.5 ± 0.19– fold (mean ±
SEM; P = .049, n = 3, two-sided paired Student’s t test) activation of Notch-1 after 2 hours. Treatment with the PI3K inhibitor LY294002 but not the JAK2 inhibitor
genistein prevented rhEpo-induced activation of Notch-1.
Figure 4. Representative FACS analysis of MCF-7 cells, stable transfected with an expression vector coding for constitutive active Notch, or an empty vector (n =
2). Expression of constitutive active Notch increased the population of BCICs.
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cells, 1.5 ± 0.4%; MDA-MB-231: GSI-treated cells, 1.5 ± 0.7%;
Epo + GSI–treated cells, 1.1 ± 0.8%) (Figure 2, C and D).
To confirm that rhEpo increased the number of BCICs in
a Notch-dependent fashion, we treated MCF-7 cells for 2 or
4 hours with 1 IU/ml rhEpo and stained cells with antibodies
against Notch–ICD, or Jagged-1, and analyzed expression
by flow cytometry. Treatment with rhEpo caused a 1.4 ±
0.16–fold (mean ± SEM, P = .041, n = 3, two-sided paired
Student’s t test) induction of Jagged-1 expression (Figure 3A)
and a 1.5 ± 0.19–fold (mean ± SEM, P = .049, n = 3, two-
sided paired Student’s t test) activation of Notch-1 after
2 hours (Figure 3B). To confirm that activated Notch signal-
ing truly increased the number of putative breast cancer stem
cells, we stably transfected MCF-7 cells with an expression
vector for a constitutively active Notch–ICD. When MCF-7–
pNICD cells were stained with antibodies against CD24 and
CD44, analyzed by flow cytometry, and compared to mock-
transfected cells, the number of CD44+/CD24/low cells was
increased in MCF-7–pNICD cells, consistent with our other
data (Figure 4).
rhEpo Activates Notch Signaling through PI3K Pathways
Signaling in response to rhEpo through the Epo receptor
is rapid and involves at least three major pathways: Janus
kinase 2 (JAK2)–dependent activation of STAT5, activation
of the Ras/Raf pathway, and PI3K/Akt–dependent/JAK2-
independent activation of nuclear factor–kappa B (NF-nB)
[31]. We previously reported activation of NF-nB in cancer
cells after treatment with rhEpo that was dependent on EpoR
expression levels [11]. Because NF-nB is known to induce
Jagged-1 expression [32], we repeated our experiment using
the PI3K inhibitor LY294002 and the JAK2 inhibitor genistein.
As expected, treatment with LY294002 but not genistein pre-
vented rhEpo-induced activation of Notch-1 (Figure 3B). As
expected, pretreatment of the cells with the GSI inhibited
activation of Notch-1 (Figure 5).
Discussion
The use of ESAs to correct chemotherapy-induced anemia
or cancer anemia is currently under debate after five large
placebo-controlled clinical trials showed increased cancer-
related death rates for patients treated with ESAs [8,10,33]
(DAHANCA 10 and Anemia of Cancer, both unpublished).
These findings could not be explained by elevated hemoglo-
bin levels, suggesting a direct effect of ESAs on cancer cells.
However, experimental evidence for a direct effect of ESAs
on cancer cells in the literature is inconclusive. Results from
studies investigating direct effects of ESAs and cancers us-
ing a broad variety of in vitro models, in vivo models, and
ESAs doses range from chemo- and radiosensitizing effects
to chemo- and radioprotective effects, whereas others re-
ported no effect at all [34–42].
EpoR was detected on cells derived from all three breast
cancer cell lines confirming previous studies [30,43]. Here
we report for the first time that EpoR is expressed on the
surface of the BCIC population. It is important to note that the
specificity of anti–EpoR antibodies is currently under debate
[44] but it has been clearly demonstrated that the EpoR sig-
nals on rhEpo binding in non–erythroid cells, including cancer
cells [45].
Using a pharmacological concentration of rhEpo (1 IU/ml),
we found that the size of the CD44+/CD24/low nonadherent
population of BCICs was increased after treatment with rhEpo.
Figure 5. Representative FACS analysis of Notch-1 activation in MCF-7
cells. Treatment with 1 IU/ml rhEpo for 2 or 4 hours (upper panel: gray line
and black line; filled histogram, control) caused activation of Notch-1. This
activation was inhibited by pretreatment with a GSI for 30 minutes at 2 and
4 hours (middle and lower panels: gray line, rhEpo; dashed line, rhEpo + GSI;
filled histogram, control).
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The increase in the number of BCICs observed after rhEpo
treatment was significant and the cells were not only viable
but, more importantly, exhibited an increased self-renewal ca-
pacity as demonstrated by primary in vitro sphere formation.
We have previously demonstrated that activation of the
Notch signaling pathway is part of the cellular stress re-
sponse to clinical doses of ionizing radiation [23]. Interest-
ingly, this effect was mediated by increased expression of
the Notch receptor ligand Jagged-1 in the non–BCIC popu-
lation that activated Notch signaling in BCICs. As for radia-
tion [23], we have shown in this study that rhEpo treatment
activated Notch signaling in BCICs. It further opens the pos-
sibility that EpoR expression may not be essential for BCICs
to respond to rhEpo directly, but indirectly as they are the
receiving part in the Notch signaling cascade, as long as the
surrounding cells in a tumor express the receptor and re-
spond to rhEpo with induction of Notch ligand expression.
The role of Notch signaling for the rhEpo-induced increase in
BCICs was further underlined by the observations that
expression of constitutive active Notch increased the number
of BCICs. As in our previous study [23], the number of BCICs
was increased in the population of cells floating on top of the
adherent cells. Comparable results were initially reported by
Ponti et al. [22] and this may reflect the fact that this popu-
lation usually contains not only dead cells but also cells under-
goingmitosis and therefore detach from the adherent population.
We have previously shown that treatment of EpoR-
expressing cancer cells activates the transcription factor
NF-nB [11]. This activation is independent of JAK2 [31], me-
diated through the PI3K pathway [46], and Jagged-1 is a
known downstream target gene of NF-nB [32]. Consistent
with these previous findings, inhibition of the PI3K but not
JAK2 prevented the increase in BCICs in response to rhEpo.
Remarkably, GSI alone did not affect the number of mammo-
spheres formed, which may indicate that GSIs are not toxic
for BCICs, rather they only interfere with the switch to sym-
metric cell division while sphere formation remains intact.
Conclusions
Taken together, our study demonstrates that rhEpo mediates
an increase in the number of BCICs in MCF-7 and MDA-MB-
231 cultures, which could be blocked by inhibition of Notch
signaling. With putative stem cells now identified in other
cancers [14,16–18], it will be interesting to investigate if ESAs
generally affect the growth of these cells also. Our study
provides a possible explanation for the unexpected negative
clinical effects of ESAs on local control and survival in cancer
patients. Clearly, using established cell lines, our study
has limitations and our observations need to be confirmed
in primary tumor cell lines derived from patient samples.
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